<DOC>
	<DOC>NCT01625455</DOC>
	<brief_summary>The purpose of this randomized, double-blinded, placebo-controlled study is to test the hypothesis that administration of aprepitant will decrease the severity of pruritus in patients with SÃ¨zary Syndrome.</brief_summary>
	<brief_title>Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Pruritus</mesh_term>
	<mesh_term>Neurokinin A</mesh_term>
	<mesh_term>Substance P</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<criteria>Known Sezary Syndrome Pruritus uncontrolled by conventional treatment. Baseline visual analogue scale &gt; 4. Age 18 through 80 years of age. Stable medication regimens for both Sezary Syndrome and pruritus for 3 months prior to study participation. Known hepatic impairment (defined as liver function tests &gt;3 times the upper limit of normal). Pregnancy (all women of childbearing potential will undergo urine betahcg testing). Concurrent use of pimozide, terfenadine, astemizole, or cisapride.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Sezary Syndrome</keyword>
	<keyword>Pruritus</keyword>
	<keyword>Aprepitant</keyword>
	<keyword>Neurokinin-1</keyword>
</DOC>